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INTRODUCTION
The tumor suppressor gene, TP53, is located on chromo-
some 17p13 and regulates cell cycle checkpoints, DNA repair,
and apoptosis, and plays a key role in carcinogenesis (1). The
TP53 gene comprises 11 exons, of which exons 2-11 encode
a transcription factor of 393 amino acids. The TP53 protein
contains distinct functional domains: the N-terminus trans-
activation domain (TAD, amino acids 1-42), the sequence-
specific DNA binding domain (DBD, amino acids 102-292),
the oligomerization domain (OD, amino acids 323-356), and
the C-terminus negative regulatory domain (amino acids 363-
393). Somatic mutations in the TP53 gene are frequent in
most human cancers, ranging between 5% and 80%, depend-
ing on the type, stage, and etiology of the tumors (2-4). 
TP53 mutational status has been widely studied in lung
cancers. It has been reported that TP53 mutations occur in
approximately 70% of small cell lung cancers and ≥50%
of non-small cell lung cancers (NSCLCs) (2-5). However, the
frequency of TP53 mutations in lung cancers varies consid-
erably among different populations, ranging 20-60% (6-9).
Moreover, the frequency and profile of TP53 mutations are
different according to the gene region examined. The pioneer
studies on TP53 mutations, in which TP53 mutations are
localized predominantly in exons 5-8 (10, 11), led to a bias in
TP53 mutation analysis, as ≥80% of TP53 mutation studies
focused on exons 5-8 (amino acids 126-306) (12, 13). However,
a meta-analysis of the studies that screened the entire TP53
gene showed that a total of 13.6% of mutations occurred out-
side exons 5-8, indicating that the entire coding region of
TP53 should be analyzed (12). 
Epidemiologic characteristics of lung cancer in Korea are
remarkably different form Western countries. In Korea, lung
cancer occurs predominantly in male smokers, and the ratio
of adenocarcinoma (AC) to squamous cell carcinoma (SCC)
is relatively low (1.12), which may be due to a very high smok-
ing rate among males (87.3%) and a low smoking rate among
females (20.3%) (14). In addition, several studies have shown
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TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
Although TP53 mutations have been widely studied in lung cancer, the majority of
studies have focused on exons 5-8 of the gene. In addition, TP53 mutations in Kore-
an patients with lung cancers have not been investigated. We searched for muta-
tions in the entire coding exons, including splice sites of the gene, in Korean patients
with non-small cell lung cancer (NSCLC). Mutations of the gene were determined
by direct sequencing in 176 NSCLCs. Sixty-nine mutations (62 different mutations)
were identified in 65 tumors. Of the 62 mutations, 12 were novel mutations. TP53
mutations were more frequent in males, ever-smokers and squamous cell carcino-
mas than in females, never-smokers and adenocarcinomas, respectively (all com-
parisons, P<0.001). Missense mutations were most common (52.2%), but frameshift,
nonsense, and splice-site mutations were frequently observed at frequencies of
18.8%, 15.9% and 10.1%, respectively. Of the 69 mutations, 9 (13.0%) were found
in the oligomerization domain. In addition, the proportion of mutations in the oligomer-
ization domain was significantly higher in adenocarcinomas than in squamous cell
carcinomas (23.5% vs. 2.9%, P=0.01). Our study provides clinical and molecular
characteristics of TP53 mutations in Korean patients with NSCLCs.
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that the prevalence of mutations in certain genes, such as epi-
dermal growth factor receptor (EGFR), KRAS, and LKB1 genes,
varies depending on the patient’s ethnicity (15, 16). Consid-
ering the differences in genetic and environmental factors
related to lung cancer, it is possible that the TP53 mutation
profile in Korean patients with lung cancer may be different
from patients in Western countries. Therefore, we searched
for TP53 mutations in Korean patients with NSCLCs and
correlated the results with clinicopathologic features. This is
the first study of TP53 mutations that examined all coding
exons and splice sites in Korean patients with lung cancers. 
MATERIALS AND METHODS
Patients and tissue samples
Primary lung tumors and matching non-malignant lung
tissues were obtained from 176 NSCLC patients who under-
went curative resection at Kyungpook National University
Hospital (Daegu, Korea) from January 2003 to July 2007,
after obtaining the approval from the Institutional Review
Board of the Hospital (Approval No., 74005-263) and the
patients’ written informed consent. All the patients includ-
ed in this study were ethnic Koreans. Patients who under-
went chemotherapy or radiotherapy prior to surgery were
excluded to avoid the effects on DNA. The clinicopatholog-
ic characteristics of the patients are summarized in Table 1.
Histologic type of the tumors was determined according to
the World Heath Organization criteria (17): 59 tumors were
SCCs (33.5%) and 117 were ACs (66.5%). There were 115
males (65.3%) and 61 females (34.7%), with age at diagno-
sis ranging from 40 to 82 yr in the males (median age, 65)
and from 37 to 79 yr in the females (median age, 62). Pati-
ents consisted of 57 never-smokers (32.4%) and 119 smok-
ers (67.6%). Of the 117 AC cases, 54 were never-smokers
(46.2%). Pathologic staging of lung cancers was determined
according to the International System for Staging Lung Can-
cer (18): 112 (63.6%) had stage I disease, 29 (16.5%) stage
II, 35 (19.9%) stage III or IV. All of the tumor and macro-
scopically normal lung tissue samples were obtained at the
time of surgery, and these were rapidly frozen in liquid nitro-
gen and stored at -80℃. Only tumors with greater than 80%
of the tumor component were sent forward for DNA extrac-
tion and mutational analysis. 
DNA extraction and mutational analysis of the TP53 gene
Genomic DNA was obtained from primary tumors and
matching normal lung tissues by overnight digestion with
sodium dodecyl sulfate and proteinase K (Life Technologies,
Rockville, MD, USA) followed by standard phenol-chloro-
form (1:1) extraction and ethanol precipitation. TP53 muta-
tional analysis of the entire coding regions, including exon-
intron boundaries, was performed by polymerase chain reac-
tion (PCR) and direct sequencing. Intron-based PCR primers
were designated based on the GenBank reference sequence
(accession no. NT_010718). The PCR reactions were per-
formed in a total volume of 20 mL containing 100 ng of geno-
mic DNA, 0.2 mM of each primer, 0.2 mM dNTPs, 1 unit
of Taq polymerase (Takara, Shuzo Co., Otus, Shiga, Japan),
and 1×reaction buffer (10 mM Tris-HCl [pH 8.3], 50 mM
KCl, and 1.5 mM MgCl2). The PCR cycle conditions consist-
ed of an initial denaturation step at 95℃for 5 min, followed
by 35 cycles at 95℃ for 30 sec; 30 sec at 53℃ to 56℃; 30
sec at 72℃; and a final elongation at 72℃ for 10 min. The
primers and conditions for PCR reactions are shown in Table
2. The PCR products were purified using a GENECLEAN
Turbo kit (Q-Biogene, Carlsbad, CA, USA). Sequencing was
Numbers in parenthesis, column percentage.
SCC, squamous cell carcinoma; AC, adenocarcinoma.
Variables SCC AC Total
Sample size 59 117 176
Age (yr), mean±SD 64.7±8.0 62.1±8.8 63.0±8.6
Sex, No (%)
Men  55 (93.2) 60 (51.3) 115 (65.3)
Women  4 (6.8) 57 (48.7) 61 (34.7)
Smoking status
Never  3 (5.1) 54 (46.2) 57 (32.4)
Ever  56 (94.9) 63 (53.8) 119 (67.6)
Pathologic stages, no (%)
Stage I 40 (67.8) 72 (61.5) 112 (63.6)
Stage II 9 (15.3) 20 (17.1) 29 (16.5)
Stage III+IV  10 (16.9) 25 (21.4) 35 (19.9)
Table 1. Patient characteristics Exon Primer sequences
Annealing
tempera-
ture (°C)
Exons 2, 3  Forward 5′ -CTGTCTCAGACACTGGCATG-3′ 54
Reverse 5′ -GAGCAGTCAGAGGACCAGG-3′
Exon 4 Forward 5′ -CGTTCTGGTAAGGACAAGGG-3′ 54
Reverse 5′ -CACTGACAGGAAGCCAAAGG-3′
Exons 5, 6 Forward 5′ -GTTGCAGGAGGTGCTTACG-3′ 53
Reverse 5′ -CATGGGGTTATAGGGAGGTC-3′
Exon 7 Forward 5′ -CCTGCTTGCCACAGGTCTC-3′ 55
Reverse 5′ -GAAGCCACAGGTTAAGAGGTC-3′
Exons 8, 9 Forward 5′ -GACAAGGGTGGTTGGGAGTAG-3′56
Reverse 5′ -CCAGGAGCCATTGTCTTTGAG-3′
Exon 10 Forward 5′ -GCTGTATAGGTACTTGAAGTGC-3′53
Reverse 5′ -CTGTGGATACACTGAGGCAAG-3′
Exon 11 Forward 5′ -GCCCTTCAAAGCATTGGTCAG-3′ 54
Reverse 5′ -CCTGGTTAGTACGGTGAAGTG-3′
Table 2. Primers and annealing temperatures for PCR and sequ-
encing analysis700 E.B. Lee, G. Jin, S.Y. Lee, et al.
done using an ABI Prism 3100 Genetic Analyzer (PE Biosys-
tems, Foster City, CA, USA). All sequence variants were con-
firmed by sequencing the products of independent PCR am-
plifications in both directions.
Statistical analysis
The association between TP53 mutations and clinicopatho-
logical characteristics was analyzed using either a chi-square
test or Fisher’s exact test. All statistical tests were two-sided,
and a P value less than 0.05 was considered to be statistical-
ly significant. 
RESULTS
Of the 176 NSCLCs, a total of 69 mutations (62 different
mutations) were detected in 65 tumors (36.9%). All the muta-
tions found in the primary tumors were absent in DNA from
the matched non-malignant lung tissues and blood lympho-
cytes, indicating that these alterations were somatic events.
There were 4 ACs with 2 mutations: 2 had an identical silent
(synonymous) mutation (c.960G>A, p.K320K in exon 9) and
one missense mutation (c.1000G>T, p.G334W in exon 10;
or c.854A>T, p.E285V in exon 8, for each); 1 had a missense
and a nonsense mutation (c.469G>T, p.V157F in exon 5; and
c.1024C>T, p.R342X in exon 10); and 1 had two missense
mutations (c.374C>T, p.T125M in exon 4; and c.1009C>T,
p.R337C in exon 10). When compared to the International
Agency for Research on Cancer (IARC) mutation database
(http://www-p53.iarc.fr), 25 of the 62 mutations were novel
mutations for lung cancer: 12 frameshift mutations, 8 mis-
sense mutations, 1 nonsense mutation, 3 splice-site muta-
tions, and 1 silent mutation. In addition, 12 of the 25 muta-
tions were novel mutations which have not been reported in
any types of cancers. Table 3 details mutations for each muta-
Age
(yr)
Gender
Smoking
status
Histology pStage Nucleotide change Region Predicted effect
Case
No.
1 72 M Current SCC IIB c.782+2T>C
� i7-intron Splicing
2 57 M Former SCC IIIA c.726C>G 7-exon p.C242W
3 64 M Former SCC IIIB c.102del1
� 4-exon Frameshift
4 74 M Current SCC IB c.641A>G 6-exon p.H214R
5 59 M Former AC IB c.469G>T 5-exon p.V157F
c.1024C>T 10-exon p.R342X
6 66 M Current AC IIB c.960G>A* 9-exon p.K320K
c.1000G>T 10-exon p.G334W
7 78 F Current AC IA c.461G>T 5-exon p.G154V
8 68 M Current AC IB c.830G>T 8-exon p.C277F
9 52 M Current AC IA c.79C>A
� 3-exon p.P27T
10 58 M Current AC IB c.854A>T* 8-exon p.E285V
c.960G>A* 9-exon p.K320K
11 41 F Never AC IB c.375+1G>A i4-intron Splicing
12 47 M Current AC IIB c.723del1 7-exon Frameshift
13 72 M Current AC IB c.1024C>T 10-exon p.R342X
14 77 M Former AC IB c.1047del
� 10-exon Frameshift
15 53 M Current SCC IB c.743G>A 7-exon p.R248Q
16 67 M Former AC IB c.1045G>T 10-exon p.E349X
17 57 M Current SCC IIIB c.374C>T* 4-exon p.T125M
18 65 M Current SCC IB c.853G>T* 8-exon p.E285X
19 55 M Current SCC IB c.641A>G 6-exon p.H214R
20 68 M Former SCC IB c.913A>T 8-exon p.K305X
21 76 M Current SCC IB c.473G>T 5-exon p.R158L
22 65 M Former SCC IB c.796G>A 8-exon p.G266R
23 66 F Current SCC IIIA c.578A>G 6-exon p.H193R
24 66 M Current SCC IIB c.818G>T 8-exon p.R273L
25 59 M Current SCC IB c.454C>A 5-exon p.P152T
26 63 M Former AC IB c.578A>G 6-exon p.H193R
27 59 M Current SCC IIB c.809T>C* 8-exon p.F270S
28 77 M Former AC IB c.794T>G* 8-exon p.L265R
29 65 M Current SCC IIIA c.583_600del18
� 6-exon Frameshift
30 54 F Never AC IB c.374C>T* 4-exon p.T125M
c.1009C>T 10-exon p.R337C
Table 3. List of mutations for each mutation-positive case
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tion-positive case. In addition to the somatic mutations, we
observed 8 germ-line variants that likely represent polymor-
phisms because they were found in matched non-malignant
lung tissues and blood lymphocytes (rs1800369C>T [D21D],
minor allele frequency [MAF]=0.392; rs1042522C>G vR-
72P], MAF=0.392; rs12947788A>G [IVS7+72], MAF=
0.301; rs12931053A>C [IVS7+92], MAF=0.301; rs1788-
2252G>A [E339K], MAF=0.006; IVS2+14T>C, MAF=
0.006; c.91G>A [V31I], MAF=0.020; and IVS3=27insGG,
MAF=0.014).
TP53 mutations were significantly more frequent in males
than in females (49.6% vs. 13.1%), in ever-smokers than in
never-smokers (49.6% vs. 10.5%), and in SCCs than in ACs
(59.3% vs. 25.6%: all comparisons, P<0.001; Table 4). How-
ever, TP53 mutations were not associated with age and pa-
thologic stage of the tumors.
Missense mutations were the most common type (36/69
[52.2%]). However, frameshift, nonsense, and splice-site muta-
tions were also commonly detected at frequencies of 18.8%
(13/69), 15.9% (11/69), and 10.1% (7/69), respectively. There
was no significant difference in mutation type according to
tumor histology. When compared to the IARC mutation
database, missense mutations were less frequent, whereas non-
sense and frameshift mutations were more frequent (Table 5).
Missense mutations occurred predominantly (31/36 [86.1%])
in the exons coding for the DBD (a part of exon 4, and exons
5-8), whereas frameshift or nonsense mutations were scattered
over the entire coding exons of the gene (Fig. 1). 
The TP53 mutation pattern is shown in Fig. 2. G:C>T:A
transversions were the most common type (16/69 [23.2%]),
followed by del or ins (13/69 [18.8%]), G:C>A:T transitions
at non-CpG sites (11/69 [15.9%]), A:T>G:C transitions (9/
31 59 M Former SCC IIIB c.818G>A 8-exon p.R273H
32 66 M Current SCC IIB c.811G>T 8-exon p.E271X
33 72 M Current SCC IIB c.97-2A>T i3-intron Splicing
34 66 M Former SCC IB c.384_387del4
� 5-exon Frameshift
35 49 M Current AC IB c.104_105ins1
� 4-exon Frameshift
36 73 M Never SCC IB c.461G>T 5-exon p.G154V
37 67 M Current SCC IA c.820G>C* 8-exon p.V274L
38 70 M Former SCC IB c.920-2A>C
� i8-intron Splicing
39 56 M Current AC IB c.473del1
� 5-exon Frameshift
40 65 M Current SCC IB c.1015G>T 10-exon p.E339X
41 69 M Current AC IB c.1001G>T 10-exon p.G334V
42 62 M Former AC IIB c.920-2A>G* i8-intron Splicing
43 63 M Current AC IB c.824G>T 8-exon p.C275F
44 63 M Current SCC IB C.601_602ins4
� 6-exon Frameshift
45 82 M Current SCC IB c.529_546del18
� 5-exon Frameshift
46 70 M Former SCC IB c.359A>T 4-exon p.K120M
47 60 F Former SCC IIB c.780del1* 7-exon Frameshift
48 62 M Current SCC IB c.993+1G>A i9-intron Splicing
49 66 M Former AC IV c.414del1
� 5-exon Frameshift
50 65 M Current SCC IA c.159G>A 4-exon p.W53X
51 56 M Former SCC IIB c.569C>T 6-exon p.P190L
52 68 F Never AC IIIA c.578A>T 6-exon p.H193L
53 73 M Current AC IB c.637C>T 6-exon p.R213X
54 54 M Current AC IIB c.581T>C* 6-exon p.L194P
55 64 M Current SCC IB c.853G>A 8-exon p.E285K
56 64 M Current SCC IB c.841G>C 8-exon p.D281H
57 47 M Current AC IIIB c.632C>T* 6-exon p.T211I
58 64 M Current SCC IB c.920-1G>A i8-intron Splicing
59 60 F Never AC IB c.532del1* 5-exon Frameshift
60 65 M Current AC IB c.1001G>T 10-exon p.G334V
61 54 M Former AC IIIB c.574C>T 6-exon p.Q192X
62 64 M Current AC IA c.490A>T 5-exon p.K164X
63 57 M Current SCC IA c.659A>G 6-exon p.Y220C
64 67 F Never AC IB c.450del1* 5-exon Frameshift
65 63 M Current AC IIIA c.503A>T 5-exon p.H168L
Age
(yr)
Gender
Smoking
status
Histology pStage Nucleotide change Region Predicted effect
Case
No.
Table 3. (Continued from the previous page)  List of mutations for each mutation-positive case
*Novel mutation for only lung cancer; 
�
Novel mutation for all type of cancers.
SCC, squamous cell carcinoma; AC, adenocarcinoma.702 E.B. Lee, G. Jin, S.Y. Lee, et al.
69 [13.0%]), and G:C>A:T transitions at CpG sites (8/69
[11.6%]). G:C>T:A transversions were more frequent in ever-
smokers than in never-smokers (24.2% vs. 14.3%), whereas
G:C>A:T transitions at CpG sites were more frequent in
never-smokers than in ever-smokers (28.6% vs. 9.7%): how-
ever, the differences were not statistically significant. In addi-
tion, no significant difference in the mutation pattern accord-
ing to tumor histology was found. 
Of the 69 mutations observed, 3 (4.3%) occurred in the
exons coding for the TAD, 46 (66.7%; 2 in exon 4, and 44
in exons 5-8) occurred in the exons coding for the DBD, 9
(13.0%) occurred in the exon 10 coding for the OD, and 11
(15.9%) occurred in splice sites or exons outside 3 major func-
tional domains (Table 6). The proportion of mutations in the
exons coding for the DBD was not significantly different
according to tumor histology (74.3% in SCCs vs. 58.8% in
ACs, P=0.17). However, the proportion of mutations in the
exon coding for the OD was significantly higher in ACs than
in SCCs (23.5% vs 2.9%, P=0.01). 
The codons with the highest mutation rates were 193, 285,
and 334 (3/69 [4.3% for each]), and followed by 125, 154,
158, 214, 273, 320, 342, and 349 (2/69 [2.9% for each]).
*Row percentage.
SCC, squamous cell carcinoma; AC, adenocarcinoma.
Variables
Mutation frequency
No. (%)*
P
Overall (n=176) 65 (36.9)
Age (yr)
≤64 (n=93) 33 (35.5) 0.67
>64 (n=83) 32 (38.6)
Gender
Male (n=115) 57 (49.6) <0.001
Female (n=61) 8 (13.1)
Smoking status
Never-smokers (n=57) 6 (10.5) <0.001
Ever-smokers (n=119) 59 (49.6)
Histologic type
SCC (n=59) 35 (59.3) <0.001
AC (n=117) 30 (25.6)
Pathologic stage
Stage I (n=112) 43 (38.4) 0.60
Stage II-IV (n=64) 22 (34.4)
Table 4. Correlation of TP53 mutations with clinicopathological
features
Numbers in parenthesis, column percentage.
*IARC TP53 Mutation Database, R13, November 2008.
SCC, squamous cell carcinoma; AC, adenocarcinoma.
Current study
Types Mutations in
SCCs (n=35)
Mutations in
ACs (n=34)
All mutations 
(n=69)
IARC data*
SCC (n=876) AC (n=776)
Missense 19 (54.3) 17 (50.0) 36 (52.2) 635 (72.4) 585 (75.3)
Frameshift 6 (17.1) 7 (20.6) 13 (18.8) 83 (9.5) 70 (9.0)
Nonsense 5 (14.3) 6 (17.6) 11 (15.9) 84 (9.6) 50 (6.4)
Splice-site 5 (14.3) 2 (5.9) 7 (10.1) 20 (2.3) 21 (2.7)
Silent 0 (0.0) 2 (5.9) 2 (2.9) 29 (3.3) 33 (4.3)
Others 25 (0.7) 16 (0.1)
Table 5. TP53 mutation types
E2 E3
TAD
Missense mutation
125 154 158
193
214 273
285
320
324
342 349
27 3435
*1 *3
201 241 260 *2
178
138150
53
192 190 220 248 265 274277
281 275
270
266271 242
211 194 164
213
305
339
337 120
152
157
168
DBD OD
E4 E5 E7 E6 E8 E10 E9 E11
Frameshift mutation Nonsense mutation Silent mutation Splice-site mutation
Fig. 1. Overview of 69 TP53 mutations. E2-E11 do not reflect the real size of each exon, but are approximately proportional to the frequen-
cy of mutations. The position of each bar indicates the approximate location of each mutation. The height of each bar correlates with the
frequency of the mutation at each location. 
*1, P128_A129 del; *2, P177_C182 del; *3, I195_N200 del.
E, exon; TAD, transactivation domain; DBD, DNA-binding domain; OD, oligomerization domain. TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer 703
Two of these, that is, codons 158 and 273, are major muta-
tion hot spots in lung cancer (Fig. 1). Mutations in codons
334, 342, and 349 were observed only in ACs. 
DISCUSSION
We described here for the first time the TP53 mutation
profile of Korean patients with NSCLCs. In the present study,
we searched for TP53 mutations in entire coding exons includ-
ing splice sites. In agreement with previous studies (4-7) and
the IARC mutation database, TP53 mutations were signifi-
cantly related to gender, smoking history, and tumor histol-
ogy. However, we report notable findings in TP53 mutation
analysis. First, a total of 36.2% (25/69) of the TP53 muta-
tions occurred outside exons 5-8. Second, although missense
mutations were the predominant type, frameshift, nonsense,
and splice-site mutations were also frequent and they com-
prised 44.9% (31/69) of the TP53 mutations observed. Third,
the proportion of mutations in the exon coding for the OD
were significantly higher in the ACs than in the SCCs. Fourth,
in the present study, TP53 mutations were detected in 59.3%
of SCCs and in 25.6% of ACs. These frequencies were com-
patible with those of the previous studies (4-7) and the IARC
mutation database. Finally, we report 12 novel mutations
which have not been reported in any types of cancers.
Analysis of the studies that screened the entire coding exons
of the TP53 gene showed that focusing on exons 5-8 led to
an unacceptable bias (12, 13). The studies that focused on
exons 5-8 have reported that most TP53 mutations were point
missense mutations and predominantly occurred in the DBD.
However, the studies that examined the entire TP53 gene
have shown that a total of 13.6% of mutations were located
outside exons 5-8, particularly in exons 4, 9, and 10 and that
in the exons outside exons 5-8, nonsense and frameshift muta-
tions were more frequent than in exons 5-8 (4, 19, 20). In
the present study, 25 (36.2%) of all the 69 mutations were
located outside exons 5-8. In addition, 18 (29.0%) of the 62
mutations detected in coding exons occurred outside exons
5-8 (1 in exon 3, 6 in exon 4, 2 in exon 9, and 9 in exon 10),
Fig. 2. TP53 mutation pattern. 
SCC, squamous cell carcinoma; AC, adenocarcinoma. Number in parentheses, percentage.
16 (23.3)
3 (4.3)
2 (2.9)
7 (10.1)
9 (13.0)
7 (20.0)
3 (8.6)
3 (8.6)
6 (17.1)
9 (26.5)
4 (11.8)
3 (8.8)
13 (18.8)
8 (11.6)
3 (8.6)
6 (17.1) 7 (20.6)
5 (14.7)
11 (15.9)
6 (17.1)
5 (14.7)
1 (2.9)
15 (24.2)
3 (4.8)
2 (3.2)
6 (9.7)
9 (14.5)
1 (14.3)
G:C>T:A
1 (14.3)
11 (17.7)
6 (9.7) 2 (28.6)
2 (28.6)
10 (16.1)
1 (14.3)
1 (2.9)
G:C>A:T at CpG
G:C>A:T at non CpG
A:T>G:C
A:T>T:A
G:C>C:G
A:T>C:G
del+ins
Numbers in parenthesis, column percentage.
*Included 7 splice-site mutations, and 4 mutations located in the other
coding regions outside three major domains. 
SCC, squamous cell carcinoma; AC, adenocarcinoma.
Domain
Mutations by histology
SCC 
(n=35)
All 
mutations
(n=69)
AC 
(n=34)
P
Transactivation domain 3 (4.3) 1 (2.9) 2 (5.9) 0.61
DNA binding domain 46 (66.7) 26 (74.3) 20 (58.8) 0.17
Oligomerization domain 9 (13.0) 1 (2.9) 8 (23.5) 0.01
Others 11 (15.9)* 7 (20.0) 4 (11.8) 0.35
Table 6. Region of TP53 mutations
All (n=69) SCC (n=35)
Ever smoker (n=62) Never smoker (n=7)
AC (n=34)704 E.B. Lee, G. Jin, S.Y. Lee, et al.
which was significantly higher than the proportion (13.6%)
in a meta-analysis of the studies that screened the entire cod-
ing exons of the TP53 gene (12). 
Another possible source of bias is related to splice-site muta-
tions. Because splice-site mutations have been thought to
be relatively infrequent and their effects have not been well-
characterized, most previous studies have not analyzed exon-
intron junctions of the gene. Therefore, in the IARC data-
base, splice-site mutations account for 2.28% and 2.70% of
all the mutations reported in SCCs and ACs of the lung, res-
pectively (Table 5). However, Varley et al. (21) recently report-
ed that germ-line splice-site mutations in 7 (17.5%) of 40
families with Li-Fraumeni syndrome, and splicing was altered
in 6 of the 7 cases with germ-line splice-site mutations. This
finding suggests the real-incidence of splice-site mutations
in sporadic human cancers is closer to this figure (12). In agree-
ment with this suggestion, 7 splice-site mutations were ob-
served in the present study, and they comprised 10.1% of
all mutations detected. In addition, 2 of the 7 splice-site muta-
tions were novel mutations that have not been reported in
any types of human cancer. 
In the present study, TP53 mutations were found in 59.3%
of SCCs and in 25.6% of ACs, which were compatible with
prior studies (4-7) and the IARC database. However, con-
sidering that most of the prior studies have only examined
exons 5-8, our findings suggest that the frequency of the TP53
mutation might be relatively low in Korean NSCLCs. The
difference in the mutation frequency, as well as the difference
in the mutation spectrum between patients with NSCLCs
from the Korean population and other ethnic populations
may be due to environmental and ethnic differences.
The TP53 protein functions as a tetramer and contains TAD
that is involved in transcriptional function, DBD, and OD
that permits oligomerization of the protein (22). It has been
demonstrated that the OD plays an important role in DNA
binding, protein-protein interactions, post-translational mod-
ifications, and TP53 degradation (23). Moreover, mutations
in the OD can inactivate wild-type TP53 protein upon a dom-
inant negative effect as mutations in the DBD that result in
a dominant negative effect by altering the conformation or
by decreasing the affinity for DNA (23). Several studies have
reported that the OD is not often mutated in human cancer,
even in the study in which the entire TP53 gene was analyzed
(24, 25), therefore little attention has been given to the OD.
However, in the present study, 9 (13.0%) of the 69 muta-
tions detected occurred in the OD, suggesting that muta-
tions in the OD occur relatively frequently in patients with
lung cancer. 
In conclusion, this study provides clinical and molecular
characteristics of TP53 mutations in Korean patients with
NSCLCs. This study shows that TP53 mutation profiles are
different from those of other ethnic populations. Our results,
may therefore contribute to a better understanding of lung
tumorigenesis in Koreans.
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